Ignite Creation Date:
2024-05-05 @ 5:04 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00376038
Status:
COMPLETED
Last Update Posted:
2012-06-04
First Post:
2006-09-12
Brief Title:
Drug Interactions From Simultaneous Administration Of Metformin And GSK189075 To Subjects With Type 2 Diabetes
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Randomized Open-label Repeat Dose Two Sequence Cross-Over Study to Determine the Effect of GSK189075 on the Pharmacokinetic Parameters of Metformin Glucophage in Subjects With Type 2 Diabetes Mellitus
Status:
COMPLETED
Status Verified Date:
2011-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
GSK189075 is intended for use as a single treatment or in combination with other treatments for tye 2 diabetes mellitus T2DM Metformin is widely used in Europe and the USA for the treatment of T2DM This study will evaluate the effect of GSK189075 on metformin levels in the blood in T2DM subjects The rationale is to look for any safety problems that may result when the 2 drugs are given together
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None